Literature DB >> 15829862

National plan for reliable tuberculosis laboratory services using a systems approach. Recommendations from CDC and the Association of Public Health Laboratories Task Force on Tuberculosis Laboratory Services.

Thomas M Shinnick1, Michael F Iademarco, John C Ridderhof.   

Abstract

Since the mid-1990s, public health laboratories have improved tuberculosis (TB) test performance, which has contributed to the resumption of the decline in TB incidence in the United States. However, to eliminate TB in the United States, further improvements are needed in laboratory services to support TB treatment, prevention, and control. A critical step is the development of an integrated system that ensures prompt and reliable laboratory testing and flow of information among laboratorians, clinicians, and TB-control officials. Challenges to developing such a system include 1) establishing lines of communication among laboratorians, clinicians, and TB-control officials; 2) expediting reporting of laboratory results, which can avoid delayed or inappropriate treatment and missed opportunities to prevent transmission; 3) developing evidence-based recommendations for use of new laboratory technologies; 4) maintaining staff proficiency in light of declining numbers of specimens to test, workforce shortages, and loss of laboratory expertise; and 5) upgrading laboratory information systems and connecting all partners. The report of the Association of Public Health Laboratories Task Force presents a framework to improve the future of TB laboratory services and describes the role of the laboratory in TB treatment and control, Task Force processes, general principles and benchmarks, and steps for the dissemination of the Task Force recommendations. This MMWR expands on the Task Force report by describing specific actions and performance measures to guide development and implementation of an integrated system for providing TB laboratory services. CDC and the Association of Public Health Laboratories have developed these guidelines so that laboratorians, clinicians, public health officials, administrators, and funding entities can work together to ensure that health-care providers and TB-control officials have the information needed to treat TB patients, prevent TB transmission, and ultimately eliminate TB in the United States.

Entities:  

Mesh:

Year:  2005        PMID: 15829862

Source DB:  PubMed          Journal:  MMWR Recomm Rep        ISSN: 1057-5987


  22 in total

1.  Direct drug susceptibility testing of Mycobacterium tuberculosis for rapid detection of multidrug resistance using the Bactec MGIT 960 system: a multicenter study.

Authors:  Salman Siddiqi; Altaf Ahmed; Sunil Asif; Digamber Behera; Mona Javaid; Jasmine Jani; Arora Jyoti; Radhika Mahatre; Dewanand Mahto; Elvira Richter; Camilla Rodrigues; Potharaju Visalakshi; Sabine Rüsch-Gerdes
Journal:  J Clin Microbiol       Date:  2011-12-07       Impact factor: 5.948

2.  Evaluation of the TB-Biochip oligonucleotide microarray system for rapid detection of rifampin resistance in Mycobacterium tuberculosis.

Authors:  Janice C Caoili; Angelina Mayorova; David Sikes; Laura Hickman; Bonnie B Plikaytis; Thomas M Shinnick
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

Review 3.  Matrix-assisted laser desorption ionization-time of flight mass spectrometry: a fundamental shift in the routine practice of clinical microbiology.

Authors:  Andrew E Clark; Erin J Kaleta; Amit Arora; Donna M Wolk
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

4.  Trends in Testing for Mycobacterium tuberculosis Complex From US Public Health Laboratories, 2009-2013.

Authors:  Frances Tyrrell; Cortney Stafford; Mitchell Yakrus; Monica Youngblood; Andrew Hill; Stephanie Johnston
Journal:  Public Health Rep       Date:  2016-12-12       Impact factor: 2.792

Review 5.  Buruli Ulcer, a Prototype for Ecosystem-Related Infection, Caused by Mycobacterium ulcerans.

Authors:  Dezemon Zingue; Amar Bouam; Roger B D Tian; Michel Drancourt
Journal:  Clin Microbiol Rev       Date:  2017-12-13       Impact factor: 26.132

6.  The combination of real-time PCR and HPLC for the identification of non-tuberculous mycobacteria.

Authors:  Jae Sun Park; Jung-In Choi; Ji-Hun Lim; Jong-Joon Ahn; Yangjin Jegal; Kwang Won Seo; Seung Won Ra; Jae Bum Jeon; Seon Ho Lee; Sung-Ryul Kim; Joseph Jeong
Journal:  Ann Lab Med       Date:  2013-08-08       Impact factor: 3.464

Review 7.  Role of the clinical mycobacteriology laboratory in diagnosis and management of tuberculosis in low-prevalence settings.

Authors:  Nicole M Parrish; Karen C Carroll
Journal:  J Clin Microbiol       Date:  2010-12-22       Impact factor: 5.948

8.  PCR as a diagnostic tool for extra-pulmonary tuberculosis.

Authors:  Ganavalli S Ajantha; Praveen C Shetty; Raghavendra D Kulkarni; Umesh Biradar
Journal:  J Clin Diagn Res       Date:  2013-04-29

Review 9.  Evaluation of the Cepheid Xpert MTB/RIF assay.

Authors:  Thomas M Shinnick; Angela M Starks; Heather L Alexander; Kenneth G Castro
Journal:  Expert Rev Mol Diagn       Date:  2014-11-06       Impact factor: 5.225

10.  New approach for drug susceptibility testing: monitoring the stress response of mycobacteria.

Authors:  Ronald J Rieder; Zhihui Zhao; Boris Zavizion
Journal:  Antimicrob Agents Chemother       Date:  2009-08-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.